Literature DB >> 23532896

Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.

Yap P Chuan1, Tania Rivera-Hernandez, Nani Wibowo, Natalie K Connors, Yang Wu, Fiona K Hughes, Linda H L Lua, Anton P J Middelberg.   

Abstract

Modularization of a peptide antigen for presentation on a microbially synthesized murine polyomavirus (MuPyV) virus-like particle (VLP) offers a new alternative for rapid and low-cost vaccine delivery at a global scale. In this approach, heterologous modules containing peptide antigenic elements are fused to and displayed on the VLP carrier, allowing enhancement of peptide immunogenicity via ordered and densely repeated presentation of the modules. This study addresses two key engineering questions pertaining to this platform, exploring the effects of (i) pre-existing carrier-specific immunity on modular VLP vaccine effectiveness and (ii) increase in the antigenic element number per VLP on peptide-specific immune response. These effects were studied in a mouse model and with modular MuPyV VLPs presenting a group A streptococcus (GAS) peptide antigen, J8i. The data presented here demonstrate that immunization with a modular VLP could induce high levels of J8i-specific antibodies despite a strong pre-existing anti-carrier immune response. Doubling of the J8i antigenic element number per VLP did not enhance J8i immunogenicity at a constant peptide dose. However, the strategy, when used in conjunction with increased VLP dose, could effectively increase the peptide dose up to 10-fold, leading to a significantly higher J8i-specific antibody titer. This study further supports feasibility of the MuPyV modular VLP vaccine platform by showing that, in the absence of adjuvant, modularized GAS antigenic peptide at a dose as low as 150 ng was sufficient to raise a high level of peptide-specific IgGs indicative of bactericidal activity.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  biomolecular engineering; modular; pre-existing immunity; vaccine; virus-like particle

Mesh:

Substances:

Year:  2013        PMID: 23532896     DOI: 10.1002/bit.24907

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  10 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.

Authors:  Elodie Beaumont; Philippe Roingeard
Journal:  Vaccine       Date:  2015-01-14       Impact factor: 3.641

Review 3.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

4.  Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.

Authors:  Braeden Donaldson; Farah Al-Barwani; Simon J Pelham; Katie Young; Vernon K Ward; Sarah L Young
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

5.  SnoopLigase peptide-peptide conjugation enables modular vaccine assembly.

Authors:  Anne-Marie C Andersson; Can M Buldun; David J Pattinson; Simon J Draper; Mark Howarth
Journal:  Sci Rep       Date:  2019-03-15       Impact factor: 4.379

Review 6.  Platform technologies for modern vaccine manufacturing.

Authors:  Hayley K Charlton Hume; Linda H L Lua
Journal:  Vaccine       Date:  2017-03-25       Impact factor: 3.641

Review 7.  Virus-like particle vaccines: immunology and formulation for clinical translation.

Authors:  Braeden Donaldson; Zabeen Lateef; Greg F Walker; Sarah L Young; Vernon K Ward
Journal:  Expert Rev Vaccines       Date:  2018-09-19       Impact factor: 5.217

8.  Immunogenicity of Multi-Target Chimeric RHDV Virus-Like Particles Delivering Foreign B-Cell Epitopes.

Authors:  María Zamora-Ceballos; Noelia Moreno; David Gil-Cantero; José R Castón; Esther Blanco; Juan Bárcena
Journal:  Vaccines (Basel)       Date:  2022-02-02

9.  Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model.

Authors:  Andrea Aebischer; Kerstin Wernike; Patricia König; Kati Franzke; Paul J Wichgers Schreur; Jeroen Kortekaas; Marika Vitikainen; Marilyn Wiebe; Markku Saloheimo; Ronen Tchelet; Jean-Christophe Audonnet; Martin Beer
Journal:  Vaccines (Basel)       Date:  2021-06-15

10.  Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations.

Authors:  Lin Zhang; Ronghong Tang; Shu Bai; Natalie K Connors; Linda H L Lua; Yap P Chuan; Anton P J Middelberg; Yan Sun
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.